Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1200/GO.20.00239 | ||||
| Año | 2020 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
PURPOSE Locally advanced cervical cancer may present with uncontrollable vaginal bleeding in up to 70% of cases. Pelvic vessel embolization has been used as an urgent maneuver for achieving fast hemostatic control. This report describes outcomes of selective pelvic vessel embolization in patients with severe bleeding due to a locally advanced cervical cancer. METHODS In this retrospective study, technical aspects, clinical variables, and bleeding-related morbidity were described. The frequency of recurrent disease and the vital status at 1 year of follow-up were determined. Analysis was performed with statistical software R, version 3.6.2. The setting was Instituto Nacional de Cancerología- Bogotá, Colombia, between January 2009 and July 2017. RESULTS A total of 47 patients were included. Median age was 44 years (range, 26-70 years). The preembolization median hemoglobin level was 7.9 g/dL (range, 5.0-11.3 g/dL). Blood transfusions were administered to 41 women (87.2%). Bleeding control was achieved in 95.7% of cases in the first 24 hours after the embolization. There were no major complications. In 17 cases (36.2%), minor complications were reported; the most common was pelvic pain. In 17.1% of cases, a second embolization was required. After 12 months of follow-up, 27.7% of patients were alive without disease, 44.7% were alive with disease, and 25.5% of them have died of cervical cancer progression. CONCLUSION Selective pelvic vessel embolization is a useful alternative in patients with locally advanced cervical cancer and life-threatening bleeding. Its impact on recurrent disease and death due to oncologic cause is not clear.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Almeciga, Adriana | Mujer |
Instituto Nacional de Cancerología - Colombia
INST NACL CANCEROL - Colombia |
| 2 | Rodriguez, Juliana | Mujer |
Instituto Nacional de Cancerología - Colombia
Fundación Santa Fe de Bogotá - Colombia INST NACL CANCEROL - Colombia FDN SANTA FE BOGOTA - Colombia |
| 3 | Beltran, Julian | Hombre |
Instituto Nacional de Cancerología - Colombia
INST NACL CANCEROL - Colombia |
| 4 | Sáenz, James | Hombre |
Instituto Nacional de Cancerología - Colombia
Universidad Militar Nueva Granada - Colombia INST NACL CANCEROL - Colombia Univ Mil Nueva Granada - Colombia |
| 5 | Merchán, Abel | Hombre |
Centro de Investigaciones Oncológicas Clínica San Diego - Colombia
Ctr Invest Oncol Oncol Clin San Diego - Colombia |
| 5 | Merchan, Abel | Hombre |
Ctr Invest Oncol Oncol Clin San Diego - Colombia
|
| 6 | Egurrola, Jorge | Hombre |
Universidad del Magdalena - Colombia
Univ Magdalena - Colombia |
| 7 | Burbano, Javier | Hombre |
Fundación Valle del Lili - Colombia
7 Fdn Valle Lili - Colombia |
| 8 | TRUJILLO-CHACON, LINA MARCELA | Mujer |
Instituto Nacional de Cancerología - Colombia
INST NACL CANCEROL - Colombia |
| 9 | Heredia, Fernando | Hombre |
Universidad de Concepción - Chile
|
| 10 | Pareja, Rene | Hombre |
Instituto Nacional de Cancerología - Colombia
Coorporación Universitaria Remington - Colombia INST NACL CANCEROL - Colombia Univ Pontificia Bolivariana - Colombia |